Gain insights into Paysign, Inc.'s Q4 2024 performance, driven by 212% growth in patient affordability revenue.

The industry needs to embrace innovation with technology towards novel drug development to remain relevant in the marketplace.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

How continent is navigating decades-old obstacles to build robust vaccine industry ANALYSIS | The African Union has embarked ...